| Literature DB >> 32228490 |
Kaname Watanabe1,2, Kayoko Katayama2, Takashi Yoshioka1, Hiroto Narimatsu3,4.
Abstract
BACKGROUND: Cancer survivors and their caregivers may have various unmet needs that are medically difficult to solve. Previous studies have suggested the relations between individuals' backgrounds and their unmet needs. We conducted a large-scale analysis to clarify the influence of individuals' backgrounds, primarily cancer type, on specific types of unmet needs.Entities:
Keywords: Cancer survivors; Caregivers; Multivariate analysis; Qualitative research; Telephone
Mesh:
Year: 2020 PMID: 32228490 PMCID: PMC7106842 DOI: 10.1186/s12885-020-06732-5
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Characteristics of the analysis subset in comparison to those of the full survey sample
| Analysis Subset | Total Surveyed | |
|---|---|---|
| ( | ( | |
| Caller’s sex, | ||
| Male | 637 (32.9) | 3470 (31.5) |
| Female | 1300 (67.1) | 7542 (68.5) |
| Survivor’s sex, | ||
| Male | 719 (37.1) | 4050 (42.0) |
| Female | 995 (51.3) | 5597 (58.0) |
| Caller’s age groups, | ||
| < 40 y | 282 (14.6) | 1529 (14.5) |
| 40–59 y | 756 (39.0) | 4294 (40.8) |
| ≥ 60 y | 830 (42.8) | 4702 (44.6) |
| Survivor’s age groups, | ||
| < 40 y | 140 (7.2) | 854 (9.8) |
| 40–59 y | 479 (24.7) | 2673 (30.5) |
| 60–69 y | 459 (23.7) | 2505 (28.6) |
| ≥ 70 y | 473 (24.4) | 2718 (31.1) |
| Relationship with survivor, | ||
| Survivor | 1054 (54.4) | 5867 (53.4) |
| Spouse | 278 (14.3) | 1771 (16.1) |
| Child | 361 (18.6) | 1961 (17.8) |
| Parent | 54 (2.8) | 337 (3.1) |
| Sibling | 64 (3.3) | 344 (3.1) |
| Other | 124 (6.4) | 708 (6.4) |
| Treatment course, | ||
| Never diagnosed with cancer | 492 (25.4) | 2721 (28.8) |
| Ongoing | 694 (35.8) | 3937 (41.6) |
| Completed | 468 (29.6) | 2804 (29.6) |
| Cancer type, | ||
| Breast | 275(14.2) | 1531 (14.1) |
| Lung | 189 (9.8) | 1061 (9.7) |
| Colorectal | 181 (9.3) | 1072 (9.8) |
| Stomach | 156 (8.0) | 918 (8.4) |
| Other | 669 (34.5) | 3705 (34.0) |
| Multi primary | 59 (3.0) | 345 (3.2) |
| Never diagnosed with cancer | 409 (21.1) | 2258 (20.7) |
| Residence, | ||
| A city designated by ordinance | 1162 (60.0) | 6519 (61.3) |
| Within Kanagawa Prefecture | 540 (27.9) | 3173 (29.8) |
| Outside Kanagawa Prefecture | 178 (9.2) | 940 (8.8) |
Unmet needs themes (frequency and description)
| % | Codebook Description | ||
|---|---|---|---|
| 1. Physical | 391 | 20.2 | Needs and issues experienced in or affecting the body, including pain, symptoms, sexual dysfunction, and care of body (such as diet, exercise, and rest). |
| 2. Financial | 86 | 4.4 | Needs related to money, insurance, and the affordability of needed services and products. |
| 3. Education/information | 570 | 29.4 | Needs related to unanswered questions and the lack of knowledge regarding what to expect as a cancer survivor, follow-up care, self-care, cancer and health research, and cancer risks, causes, and prevention. |
| 4. Personal control | 30 | 1.5 | Needs related to an individual’s ability to maintain autonomy in terms of the physical self (sexual function, evacuation, and ambulation) and the social self (disclosure about cancer and ability to make plans and socialize). Also includes wishes to return to “normal” and finding a “new normal.” |
| 5. System of care | 76 | 3.9 | Needs related to the health care system, including constraints, flaws, and limitations that affect early detection, diagnosis, treatment, follow-up care, continuity of care, and inadequate response from health care providers. |
| 6. Resources | 649 | 33.5 | Needs related to availability and access to supplies, equipment, therapies and medications (including alternative and complementary), and transportation services. |
| 7. Emotions/mental health | 379 | 19.6 | Needs related to psychological issues, including fear (recurrence, new cancers, death, and dying), depression, anxiety, and negative feelings (mistrust toward body, anger, and guilt). |
| 8. Social support | 30 | 1.5 | Needs related to psychosocial and interpersonal issues, including intimacy, access to support groups, opportunities to use one’s own experiences to help others, and participation in social situations. |
| 9. Societal | 8 | 0.4 | Needs revealed from respondents’ commentary about conditions and issues related to society’s response to cancer, including social norms, discrimination, misinformation, policies, and resource allocation (insurance coverage). |
| 10. Communication | 148 | 7.6 | Needs related to engaging in discourse (talking) and information exchange (explaining) with others (including patients and doctors and patients and caregivers) and medical providers regarding cancer, cancer experience, and reconciliation with others. |
| 11. Provider relationship | 179 | 9.2 | Needs related to trust in health care providers, including decision-making, follow-through, follow-up, and support. |
| 12. Cure | 474 | 24.5 | Needs related to a wish for a cure for cancer and hopes for effective treatments (including through alternative medicine) for one’s self and for others. |
| 13. Body image | 7 | 0.4 | Needs related to negative perception of body, including feeling unattractive and/or ashamed and loss of trust in body. |
| 14. Survivor identity | 1 | 0.1 | Pertains to the respondent either explicitly identifying or not identifying as a cancer survivor because the respondent does not like the term “survivor” or feels that he or she has not reached a specific milestone to be called a survivor (e.g., not still in treatment or living a specific number of years since the diagnosis). |
| 15. Employment | 28 | 1.4 | Needs pertaining to maintaining or obtaining a source of income that is appropriate given the cancer experience. |
| 16. Existential | 11 | 0.6 | Needs pertaining to attaining peace in life and spirituality and making sense or meaning of the cancer experience. |
Average number of unmet needs stratified by each characteristics
| n | Mean value | Standard Deviation | Median | Inter-quartile range | ||
|---|---|---|---|---|---|---|
| Total | 1938 | 1.58 | 0.86 | 1.00 | 1.00–2.00 | |
| Caller’s sex | ||||||
| Male | 637 | 1.56 | 0.83 | 1.00 | 1.00–2.00 | |
| Female | 1300 | 1.59 | 0.87 | 1.00 | 1.00–2.00 | |
| Survivor’s sex | ||||||
| Male | 719 | 1.65 | 0.89 | 1.00 | 1.00–2.00 | |
| Female | 995 | 1.60 | 0.88 | 1.00 | 1.00–2.00 | |
| Caller’s age group | ||||||
| 20–30 | 282 | 1.64 | 0.92 | 1.00 | 1.00–2.00 | |
| 40–50 | 756 | 1.61 | 0.88 | 1.00 | 1.00–2.00 | |
| ≥ 60 | 830 | 1.56 | 0.83 | 1.00 | 1.00–2.00 | |
| Survivor’s age group | ||||||
| < 40 | 140 | 1.49 | 0.78 | 1.00 | 1.00–2.00 | |
| 40–59 | 479 | 1.58 | 0.85 | 1.00 | 1.00–2.00 | |
| 60–69 | 459 | 1.66 | 0.94 | 1.00 | 1.00–2.00 | |
| ≥ 70 | 473 | 1.63 | 0.86 | 1.00 | 1.00–2.00 | |
| Relationship with survivor | ||||||
| Survivor | 1054 | 1.53 | 0.81 | 1.00 | 1.00–2.00 | |
| Spouse | 278 | 1.64 | 0.94 | 1.00 | 1.00–2.00 | |
| Child | 361 | 1.71 | 0.96 | 1.00 | 1.00–2.00 | |
| Parent | 54 | 1.57 | 0.81 | 1.00 | 1.00–2.00 | |
| Sibling | 64 | 1.69 | 0.79 | 2.00 | 1.00–2.00 | |
| Other | 124 | 1.47 | 0.80 | 1.00 | 1.00–2.00 | |
| Treatment course | ||||||
| Never got | 492 | 1.52 | 0.75 | 1.00 | 1.00–2.00 | |
| Ongoing | 694 | 1.78 | 0.98 | 1.00 | 1.00–2.00 | |
| Completed | 468 | 1.56 | 0.82 | 1.00 | 1.00–2.00 | |
| Symptom | ||||||
| Yes | 1149 | 1.66 | 0.92 | 1.00 | 1.00–2.00 | |
| No | 726 | 1.48 | 0.77 | 1.00 | 1.00–2.00 | |
| Residence | ||||||
| A city designated by ordinance | 1162 | 1.57 | 0.84 | 1.00 | 1.00–2.00 | |
| Within Kanagawa Prefecture | 540 | 1.61 | 0.91 | 1.00 | 1.00–2.00 | |
| Outside Kanagawa Prefecture | 178 | 1.60 | 0.86 | 1.00 | 1.00–2.00 | |
| Past consultation history at KCCa | ||||||
| Yes | 120 | 1.33 | 0.64 | 1.00 | 1.00–2.00 | |
| No | 1818 | 1.60 | 0.87 | 1.00 | 1.00–2.00 | |
| Cancer type | ||||||
| Breast | 275 | 1.71 | 0.97 | 1.00 | 1.00–2.00 | |
| Lung | 189 | 1.66 | 0.89 | 1.00 | 1.00–2.00 | |
| Colorectal | 181 | 1.57 | 0.82 | 1.00 | 1.00–2.00 | |
| Stomach | 156 | 1.63 | 0.89 | 1.00 | 1.00–2.00 | |
| Other | 669 | 1.63 | 0.87 | 1.00 | 1.00–2.00 | |
| Multi primary cancer | 59 | 1.75 | 1.20 | 1.00 | 1.00–2.00 | |
| Never diagnosed with cancer | 409 | 1.34 | 0.63 | 1.00 | 1.00–2.00 | |
| Call duration | p < 0.0001 | |||||
| < 15 min | 1141 | 1.37 | 0.63 | 1.00 | 1.00–2.00 | |
| ≥ 15 min | 797 | 1.89 | 1.04 | 2.00 | 1.00–2.00 |
aKanagawa Cancer Center
Logistic regression analysis (survivors)
| Odds ratio (95% Confidence interval) | ||||||
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male (reference) | ||||||
| Female | 2.50 (1.54–4.07)* | 0.52 (0.22–1.21) | 0.79 (0.54–1.15) | 1.95 (0.59–6.42) | 1.19 (0.47–3.05) | 0.62 (0.43–0.91)* |
| Age group (in years) | ||||||
| < 40, 40–59, 60–69, ≥ 70 | 1.25 (1.00–1.57) | 1.03 (0.70–1.51) | 0.94 (0.78–1.13) | 0.80 (0.46–1.39) | 0.77 (0.49–1.22) | 0.98 (0.81–1.18) |
| Cancer type | ||||||
| Breast (reference) | ||||||
| Colon | 1.05 (0.52–2.10) | 0.52 (0.15–1.81) | 1.11 (0.59–2.08) | 0.59 (0.07–5.12) | 1.99 (0.44–9.08) | 1.34 (0.70–2.60) |
| Lung | 0.72 (0.31–1.69) | 0.15 (0.02–1.31) | 1.72 (0.87–3.43) | 0.78 (0.09–7.02) | 0.85 (0.09–7.93) | 1.39 (0.67–2.87) |
| Stomach | 0.96 (0.44–2.10) | 0.27 (0.05–1.40) | 1.27 (0.63–2.58) | 1.94 (0.34–11.00) | 1.56 (0.26–9.24) | 1.49 (0.73–3.03) |
| Other | 0.78 (0.45–1.33) | 0.53 (0.20–1.35) | 1.11 (0.69–1.81) | 1.17 (0.35–3.95) | 1.56 (0.47–5.20) | 1.23 (0.74–2.04) |
| Multi primary | 2.33 (0.85–6.43) | 0.35 (0.04–2.94) | 0.49 (0.16–1.53) | 3.97 (0.67–23.40) | 1.95 (0.21–18.40) | 1.25 (0.47–3.31) |
| Never diagnosed with cancer | 0.41 (0.17–0.97)* | 0.25 (0.06–0.98)* | 1.77 (1.00–3.13) | 0.00 (0.00-Inf) | 1.83 (0.47–7.20) | 1.40 (0.77–2.54) |
| Treatment course | ||||||
| Pretreatment (reference) | ||||||
| Ongoing | 5.08 (2.64–9.78)* | 0.71 (0.32–1.59) | 1.28 (0.85–1.93) | 1.31 (0.43–3.96) | 0.70 (0.25–1.98) | 0.51 (0.34–0.78)* |
| Completed | 5.35 (2.74–10.40)* | 0.91 (0.41–2.06) | 0.78 (0.52–1.18) | 0.28 (0.05–1.47) | 0.69 (0.26–1.80) | 0.68 (0.46–1.01) |
| Residence | ||||||
| CDOa (reference) | ||||||
| Within KPb | 1.12 (0.74–1.70) | 0.85 (0.42–1.73) | 0.75 (0.53–1.07) | 1.19 (0.44–3.22) | 1.44 (0.64–3.25) | 1.16 (0.82–1.65) |
| Outside KPb | 0.22 (0.06–0.79)* | 0.80 (0.18–3.58) | 0.90 (0.45–1.78) | 1.67 (0.34–8.25) | 0.64 (0.08–5.12) | 1.51 (0.78–2.95) |
| Symptom | ||||||
| Yes (reference) | ||||||
| No | 8.69 (5.35–14.10)* | 0.67 (0.35–1.29) | 0.46 (0.33–0.64)* | 0.99 (0.38–2.59) | 0.79 (0.35–1.76) | 0.69 (0.50–0.96)* |
| Past consultation history at KCCc | ||||||
| Yes (reference) | ||||||
| No | 1.22 (0.65–2.28) | 1.91 (0.75–4.81) | 1.18 (0.68–2.06) | 0.53 (0.07–4.16) | 0.91 (0.21–4.00) | 0.54 (0.27–1.07) |
| Sex | ||||||
| Male (reference) | ||||||
| Female | 1.60 (1.05–2.43)* | 1.76 (0.38–8.23) | 1.81 (0.80–4.08) | 1.25 (0.72–2.17) | 0.77 (0.51–1.15) | 0.34 (0.10–1.21) |
| Age group (in years) | ||||||
| < 40, 40–59, 60–69, ≥ 70 | 0.95 (0.78–1.16) | 1.30 (0.69–2.47) | 1.18 (0.82–1.70) | 0.98 (0.75–1.29) | 1.03 (0.84–1.25) | 0.37 (0.20–0.67)* |
| Cancer type | ||||||
| Breast (reference) | ||||||
| Colon | 0.83 (0.43–1.62) | 0.00 (0.00-Inf) | 1.28 (0.48–3.41) | 1.96 (0.86–4.48) | 1.03 (0.52–2.04) | 0.00 (0.00-Inf) |
| Lung | 0.73 (0.33–1.61) | 0.00 (0.00-Inf) | 0.46 (0.10–2.17) | 1.88 (0.73–4.83) | 1.46 (0.71–3.02) | 0.27 (0.02–2.86) |
| Stomach | 0.93 (0.45–1.93) | 0.41 (0.04–4.15) | 0.46 (0.10–2.20) | 1.17 (0.41–3.31) | 1.13 (0.53–2.42) | 0.17 (0.02–1.86) |
| Other | 0.91 (0.56–1.47) | 0.43 (0.10–1.88) | 0.63 (0.26–1.49) | 1.16 (0.57–2.36) | 1.14 (0.68–1.92) | 0.61 (0.19–1.98) |
| Multi primary | 0.89 (0.33–2.40) | 2.03 (0.32–13.00) | 2.00 (0.57–7.00) | 1.84 (0.55–6.18) | 0.98 (0.35–2.73) | 0.00 (0.00-Inf) |
| Never diagnosed with cancer | 1.52 (0.85–2.71) | 0.27 (0.03–2.58) | 0.31 (0.07–1.45) | 1.43 (0.59–3.44) | 1.01 (0.53–1.93) | 0.00 (0.00-Inf) |
| Treatment course | ||||||
| Pretreatment (reference) | ||||||
| Ongoing | 1.14 (0.72–1.79) | 1.36 (0.32–5.78) | 1.48 (0.66–3.31) | 1.63 (0.86–3.09) | 0.97 (0.63–1.48) | 1.01 (0.29–3.55) |
| Completed | 1.23 (0.79–1.91) | 1.42 (0.31–6.46) | 0.68 (0.26–1.73) | 1.26 (0.66–2.42) | 0.53 (0.34–0.82)* | 2.72 (0.86–8.57) |
| Residence | ||||||
| CDOa (reference) | ||||||
| Within KPb | 1.18 (0.82–1.70) | 0.30 (0.07–1.38) | 1.20 (0.63–2.30) | 1.18 (0.71–1.94) | 1.20 (0.83–1.74) | 1.03 (0.41–2.58) |
| Outside KPb | 0.79 (0.35–1.79) | 1.01 (0.12–8.62) | 0.39 (0.05–3.02) | 0.85 (0.29–2.54) | 1.92 (0.98–3.75) | 0.00 (0.00-Inf) |
| Symptom | ||||||
| Yes (reference) | ||||||
| No | 1.78 (1.25–2.53)* | 1.21 (0.41–3.61) | 1.31 (0.70–2.46) | 1.49 (0.92–2.42) | 0.56 (0.40–0.79)* | 1.59 (0.62–4.10) |
| Past consultation history at KCCc | ||||||
| Yes (reference) | ||||||
| No | 0.85 (0.47–1.55) | 0.00 (0.00-Inf) | 1.13 (0.42–3.03) | 0.62 (0.24–1.60) | 0.31 (0.13–0.74)* | 0.44 (0.05–3.48) |
*p < 0.05, aA city designated by official ordinance, bKanagawa prefecture, cKanagawa Cancer Center